Multiple standards of care in non-small-cell lung cancer after EGFR-TKI therapy: progress, fragmentation, or inevitability?

The Lancet · 7 Nov 2026 · Journal Article

Saw, Aldea

The abstract is read at the publisher; the summary is JClub's.

There's no AI summary of this paper here yet.

Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.

Pan-RAS Inhibitor Shows Activity in Advanced Lung Cancer.
Cancer Discovery · 3 Sept 2026 · News
AI summary · may contain errors
Daraxonrasib, a first-in-class pan-RAS inhibitor, shrank tumors in more than 30% of previously treated RAS-mutant non-small cell lung cancer patients.
- In the news
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42689323
Open in JClub
How a Rare Inherited Lung Cancer Mutation Took Root in Appalachia.
Cancer Discovery · 17 Sept 2026 · News
AI summary · may contain errors
A germline EGFRT790M variant linked to lung cancer is concentrated in Southern Appalachia, reflecting its introduction to the United States by European settlers in the 1700s.
- In the news
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42752783
Open in JClub
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.
New England Journal of Medicine · 20 Aug 2026 · Randomized Controlled Trial
AI summary · may contain errors
First-line sunvozertinib improves progression-free survival versus carboplatin-pemetrexed in advanced nonsquamous NSCLC with EGFR exon 20 insertions, reaching 10.3 vs 7.5 months.
- 17 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42212913
Open in JClub

Journals this month

All journals →

Topics moving, week to 13 Nov 2026

All topics →

By field

All journals by field →

Multiple standards of care in non-small-cell lung cancer after EGFR-TKI therapy: progress, fragmentation, or inevitability?

Related in JClub

Pan-RAS Inhibitor Shows Activity in Advanced Lung Cancer.

How a Rare Inherited Lung Cancer Mutation Took Root in Appalachia.

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.

Browse JClub